Protective Effects of Levosimendan and Iloprost on Lung Injury Induced by Limb Ischemia-Reperfusion: A Rabbit Model

Journal of Surgical Research

Volumn 147, Issue 1, 2008, Pages 138-142

  Yasa, Haydar ^a   Yakut, Necmettin ^b   Emrecan, Bilgin ^c   Ergunes, Kazim ^a   Ortac, Ragip ^d   Karahan, Nagihan ^a   Ozbek, Cengiz ^a   Gurbuz, Ali ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Gazi Hospital   (Turkey)

^c PAMUKKALE UNIVERSITY   (Turkey)

^d Behcet Uz Children's Hospital   (Turkey)

Author keywords

iloprost; ischemia; levosimendan; lung reperfusion damage

Indexed keywords

CREATINE KINASE; ILOPROST; LACTATE DEHYDROGENASE; LEVOSIMENDAN; MALONALDEHYDE; POTASSIUM; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PH; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FEMORAL ARTERY; HISTOPATHOLOGY; LIMB ISCHEMIA; LOADING DRUG DOSE; LUNG HEMODYNAMICS; LUNG INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALS; DISEASE MODELS, ANIMAL; EXTREMITIES; FEMALE; HYDRAZONES; ILOPROST; LUNG; MALE; MALONDIALDEHYDE; PYRIDAZINES; RABBITS; REPERFUSION INJURY;

EID: 43049119601     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.08.002     Document Type: Article

References (23)

1. Troyer-Caudle J. Reperfusion injury. J Vasc Nurs 11 (1993) 76
2. Crinnion J.N., Homer-Vanniasinkam S., and Gough M.J. Skeletal muscle reperfusion injury: Pathophysiology and clinical considerations. Cardiovasc Surg 1 (1993) 317
3. Adams Jr. J.G., Dhar A., Shukla S.D., et al. Effect of pentoxifylline on tissue injury and platelet-activating factor production during ischemia-reperfusion injury. J Vasc Surg 21 (1995) 742
4. Sucu N., Unlu A., Tamer L., et al. Effects of trimetazidine on tissue damage in kidney after hind limb ischemia-reperfusion. Pharmacol Res 46 (2002) 345
5. Neary P., and Redmond H.P. Ischemia-reperfusion injury and the systemic inflammatory response syndrome. In: Grace P.A., and Mathie R.T. (Eds). Ischemia-reperfusion injury (1999), Blackwell Science, London 123
6. Levinson R.M., Shure D., and Moser K.M. Reperfusion pulmonary edema after pulmonary artery thromboendarterectomy. Am Rev Respir Dis 134 (1986) 1241
7. Fantone J.C., Marasco W.A., Elgas L.J., et al. Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol 115 (1984) 9
8. Simpson P.J., Mitsos S.E., Ventura A., et al. Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 113 (1987) 129
9. Baltalarli A., Ozcan V., Bir F., et al. Ascorbic acid (vitamin C) and iloprost attenuate the lung injury caused by ischemia/reperfusion of the lower extremities of rats. Ann Vasc Surg 20 (2006) 49
10. Emrecan B., Tulukoglu E., Bozok S., et al. Effects of iloprost and pentoxifylline on penal ischemia-reperfusion in rabbit model. Eur J Med Res 11 (2006) 295
11. Follath F., Cleland J.G., Just H., Steering Committee, and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO Study): A randomized double-blind trial. Lancet 360 (2002) 196
12. Parissis J., Adamopoulos S., Antoniades C., et al. Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93 (2004) 1309
13. Belkin M., Wright J.G., and Hobson R.W. Iloprost infusion decreases skeletal muscle ischemia-reperfusion injury. J Vasc Surg 11 (1990) 77
14. Task force appointed by the Board of Directors, American Heart Association. Position of the American Heart Association on Research Animal Use. News from the American Heart Association 71 (1985) 849
15. Uchiyama M., and Mihara M. Determination of maloaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86 (1978) 271
16. Mazzone A., Mazzucchelli I., Fossati G., et al. Iloprost effects on phagocytes in patients suffering from ischaemic diseases: In vivo evidence for down regulation of αMβ2 integrin. Eur J Clin Invest 26 (1996) 860
17. Carden D.L., and Granger D.L. Pathophysiology of ischemia-reperfusion injury. J Pathol 190 (2000) 255
18. Murraf J.F., Matthay M.A., Luce J.M., et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138 (1988) 720
19. Araki H., and Lefer A.M. Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver. Am J Physiol 238 (1980) H176
20. Haikala H., Kaivola J., Nissinen E., et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27 (1995) 1859
21. Bowman P., Haikala H., and Paul R.J. Levosimendan, a calcium smooth sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 288 (1999) 316
22. Yokoshiki H., Katsube Y., Sunagawa M., et al. Levosimendan, a novel Ca sensitizer, activates the glibenclamide-sensitize K channel in rat arterial myocytes. Eur J Pharmacol 333 (1996) 249
23. Kertsen J.R., Montgomery M.W., Pagel P.S., et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 90 (2000) 5